Results 171 to 180 of about 137,029 (384)

Infusion reaction to infliximab biosimilar after transitioning from infliximab [PDF]

open access: yesJAAD Case Reports, 2021
Shanthi Narla   +3 more
openaire   +4 more sources

The Impact of Methotrexate on Cardiovascular Outcomes in Psoriasis: A Systematic Review and Meta‐Analysis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa   +2 more
wiley   +1 more source

Incidence and Clinical Characteristics of Active Tuberculosis in Psoriasis Patients From a High-Burden Setting: An 18-Year Retrospective Study of 86 Patients. [PDF]

open access: yesExp Dermatol
ABSTRACT Real‐world data on concurrent psoriasis and active tuberculosis (TB) remain limited, particularly in high TB‐burden settings. This retrospective study evaluated the incidence, prevalence, and clinical characteristics of psoriasis patients with active TB who had received topical or systemic treatments.
Trakanwittayarak S   +5 more
europepmc   +2 more sources

Association of Short‐Term Wildfire Air Pollution Exposure and Health Care Usage: A Cross‐Sectional Study Among Patients With Psoriasis From the Bay Area, United States

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Wildfire air pollution causes many adverse environmental and health effects, including adverse skin reactions. However, whether wildfire‐associated air pollution and psoriasis disease activity are associated remains unknown. Objectives To examine the association between short‐term exposure to air pollution from wildfires and rates ...
Johan Anker Chrom Allerup   +5 more
wiley   +1 more source

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

open access: yesClinical and Experimental Gastroenterology, 2009
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj  

Sequencing of Biologic Therapy in Hidradenitis Suppurativa: A Real‐World Analysis of Treatment in Over 15,000 Patients

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background The management of moderate to severe hidradenitis suppurativa (HS) is complex with secondary failure of monoclonal antibodies frequent. Real‐world evidence regarding the treatment landscape before starting biologic therapy has been well‐documented, however, the role of switching between biologic agents is less well‐described ...
James Pham   +5 more
wiley   +1 more source

Infliximab associated cholestatic liver disease [PDF]

open access: bronze, 2000
Vanessa V. Menghini, Amindra S. Arora
openalex   +1 more source

Successful Treatment of Spesolimab in a Haemodialysis Patient With Acutely Flaring Generalised Pustular Psoriasis

open access: yesJEADV Clinical Practice, EarlyView.
Capsule Summary Generalised pustular psoriasis is one of the severe dermatological disorders. The use of biologics in psoriatic patients with end‐stage renal disease is rare, and the safety information on biologics treatment in such patients is limited.
Yasuyuki Fujita   +4 more
wiley   +1 more source

Role of astrocyte in neuroinflammation‐induced loss in neuroplasticity and subsequent onset of depression: A systematic review

open access: yesNeuroprotection, EarlyView.
Mechanistic crosstalk between microglia and astrocytes in major depressive disorder. Abstract Major depressive disorder (MDD) is a complex psychiatric condition increasingly linked to chronic neuroinflammation, particularly in the context of aging, stress, and systemic comorbidities.
Gaurav Singhal   +2 more
wiley   +1 more source

Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse

open access: bronze, 2000
Lisa Toy   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy